# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Goldman Sachs Conf
- Goldman Sachs Conf
Cantor Fitzgerald analyst Sarah James reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $600 price target.
Stephens & Co. analyst Scott Fidel reiterates Elevance Health (NYSE:ELV) with a Overweight and maintains $615 price target.
B of A Securities analyst Kevin Fischbeck maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $...
Elevance Health (NYSE:ELV) announced today that senior management is scheduled to present at Bernstein's 40th Annual Strate...